Autodesk (ADSK) to Invest $100M in 3D Printing Oct 30, 2014 09:02AM

Autodesk, Inc.(NASDAQ: ADSK) has announced that it intends to invest up to $100 million in 3D printing companies over the next several years. The Spark Investment Fund, which will be operated within Autodesk, is the first of its kind for the 3D printing industry and will invest in entrepreneurs, startups and researchers who push the boundaries of 3D printing technology and accelerate the new industrial revolution.

Earlier this year, Autodesk announced Spark, an open and free* software platform for 3D printing that will connect digital information to 3D printers in a new way. Spark will connect to any hardware and be materials agnostic, and the company invites the entire 3D printing community to collaborate, build and improve the platform, its associated Ember 3D printer and materials.

Companies and individuals developing groundbreaking hardware, software, materials, marketplaces and maker spaces are encouraged to apply to participate in the Spark Investment Fund’s investment portfolio. In addition to the financial investment, Spark Investment Fund recipients will become part of the Spark partner program and have access to marketing and other developer services available to Spark partners. It is through this unique combination of strategic investment and value-added partnership opportunity that Autodesk seeks to extend and empower the Spark ecosystem and spur innovation toward a more mature 3D printing experience.

“The days of taking a closed, top-down approach to innovating for additive manufacturing are behind us. Numerous industries recognize the value of tapping into entrepreneurs or startups with better ideas and approaches, and 3D printing is no exception,” said Samir Hanna, vice president and general manager, Consumer Products and 3D Printing, at Autodesk. “The Spark Investment Fund will empower innovators to improve 3D printing, and to help us unlock the tremendous promise of this technology.”

Chembio Diagn (CEMI) Reports DPP HIV 1/2 Assay Given CLIA Waiver From FDA Oct 30, 2014 08:56AM

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care (POC) diagnostic tests and technology, today announced that the U.S. Food and Drug Administration (FDA) granted a CLIA Waiver for the Company's DPP® HIV 1/2 Assay. Chembio's DPP® HIV 1/2 Assay was FDA-approved previously, and the CLIA Waiver will allow Chembio to expand into important new channels that are closest to patient care including physician-office-lab (POL) facilities, clinics and other community healthcare providers.

Chembio's DPP® HIV 1/2 Assay detects HIV antibodies in oral fluid or blood and uses the Company's patented Dual Path Platform (DPP®) technology, which offers excellent sensitivity and specificity. The product's unique SampleTainer® specimen collection bottle is a safe, closed system for collecting potentially infectious samples. The DPP® HIV 1/2 Assay is one of only two FDA approved, CLIA-waived oral fluid HIV 1/2 rapid tests available in the U.S.

"Accurate diagnostic testing is an important tool in the battle against HIV/AIDS," stated John Sperzel, CEO of Chembio. "Our DPP® HIV 1/2 Assay combines excellent sensitivity and specificity, simple and safe oral fluid sample collection, and exceptional ease of use. We believe this combination will lead to more testing, which will result in increased detection, earlier treatment and lower exposure rates. We recently signed agreements with several major U.S. distributors for the DPP® HIV 1/2 and HIV 1/2 STAT-PAK® Assays and, with receipt of this latest waiver, we will expand our U.S. sales and marketing effort as planned."

The U.S. Congress passed the Clinical Laboratory Improvement Amendments (CLIA) in 1988 to establish standards for all laboratory testing and amended it in 2008 to establish more stringent guidelines for in-vitro diagnostics. CLIA standards require that only accurate and easy-to-use tests are performed in the physician's office. The FDA determines whether a device is CLIA-waived based on extensive evaluations conducted in a CLIA-waived environment by intended users such as physicians, nurses and medical assistants.

Chembio's DPP® HIV 1/2 and HIV 1/2 STAT-PAK® Assays are both manufactured in the U.S. by Chembio. For more information on any of the Chembio-branded products please contact our customer service team at 1.844.CHEMBIO or visit us at:

Western Gas Partners LP (WES) Prices 7.5M Common Offering at $70.85/Unit Oct 30, 2014 08:51AM

Western Gas Partners LP (NYSE: WES) announced that it has priced its public offering of 7,500,000 common units representing limited partner interests. Western Gas Partners (the "Partnership") has granted the underwriters a 30-day option to purchase up to 1,125,000 additional common units. The common units were offered to the public at $70.85 per unit. The offering is expected to settle and close on November 4, 2014, subject to customary closing conditions. The Partnership expects to use the net proceeds from the offering, including any net proceeds received from the exercise of the underwriters' option to purchase additional common units, to fund a portion of the cash purchase price of its pending Nuevo Midstream, LLC acquisition.

The closing of the Nuevo acquisition is not conditioned on the closing of the common units offering, and the common units offering is not conditioned on the Nuevo acquisition closing. If the Nuevo acquisition is not consummated for any reason, the Partnership intends to use the net proceeds from the offering for general partnership purposes, including the repayment of borrowings under its revolving credit facility.

UBS Investment Bank, Morgan Stanley, Wells Fargo Securities, Barclays, BofA Merrill Lynch, Citigroup, Deutsche Bank Securities, RBC Capital Markets, Credit Suisse and Goldman, Sachs & Co. are acting as joint book-running managers for the offering.

Hemispherx Biopharma (HEB) Reports Evidence Based Potential of Ampligen Against Ebola Oct 30, 2014 08:36AM

Hemispherx Biopharma (NYSE: HEB) reported today a new peer reviewed publication entitled, "The Quest for Effective Ebola Treatment; Ebola VP35 is an Evidence-Based Target for dsRNA Drugs" in the Nature Group's current issue of Emerging Microbes and Infections (October 29, 2014). This publication was authored by affiliates of Hemispherx. The publication provides an illustration of the crystallographic coordinates of a truncated VP35 complex with dsRNA.

Death from Ebola virus (EBOV) infection is associated with markedly impaired coagulation and innate immunity cascades, increased production of pro-inflammatory cytokines, profound immune suppression resulting in peripheral T lymphocyte apoptosis, and a lack of adaptive immunity (Fields Virology 923-956, 2013). By contrast, survivors of infection by EBOV develop an effective immune response with the production of EBOV neutralizing antibodies. Early events in EBOV infection influence the patient's ability to develop an effective immune response. The success of EBOV replication is dependent on viral inhibition of initial innate immune responses to infection. Disarming innate immune responses is a common mechanism employed by highly pathogenic human viruses, including those of the influenza and coronavirus families (Antiviral Res 100:615, 2013). EBOV is one of the more successful of the emerging highly pathogenic viruses in evasion of innate immune mechanisms.

Kandi Technologies Group (KNDI) to Launch Car-Share Program in Chengdu; Will Deliver 1,000 Vehicles Before End of 2014 Oct 30, 2014 08:34AM

Kandi Technologies Group (NASDAQ: KNDI) announced that the Car-Share Program is expected to be launched in Chengdu with the delivery of 1,000 Kandi brand electric vehicles before the year-end.

Chengdu is the provincial capital of Sichuan province in Southwest China with over 14 million inhabitants. Being one of the most important centers for economic, technology, communication, and education in Western China, Chengdu has been chosen by the government to be one of the national renewable energy automobile pilot cities. Purchasers of Kandi's SMA7000BEV and SMA7001BEV models are eligible to receive, on a per car basis, the national government subsidy of RMB 47,500.00 (Approximately USD 7,738.00) and the local government subsidy of RMB 47,500.00 (Approximately USD 7,738.00) from Sichuan provincial government and Chengdu municipal government combined.

ZuoZhongYou (Chengdu) Electric Vehicle Service Co., Ltd. ("ZZY-Chengdu"), a wholly owned subsidiary of Zhejiang ZuoZhongYou Electric Vehicle Service Co., Ltd. ("ZZY") has obtained the registration approval from the local State Administration of Industry and Commerce for the formation of ZZY-Chengdu. Upon the completion of ancillary procedures for ZZY-Chengdu's establishment, the Car-Share Program and Long-term Group Leasing Program will be officially launched in Chengdu by the end of this year.

More Corporate News

View Older Stories

Oct 30, 2014 08:06AM Myos Corporation (MYOS) Reports Data Showing Fortetropin's Anti-Inflammatory Properties
Oct 30, 2014 07:38AM S&T Bancorp (STBA), Integrity Bancshares Enter Merger Pact
Oct 30, 2014 07:17AM Omeros Corp. (OMER) Omidria Receives Pass-Through Status from Center for Medicare & Medicaid Services
Oct 30, 2014 06:52AM GW Pharma (GWPH) Commences Phase 2/3 Trial of Epidiolex
Oct 30, 2014 06:28AM Facebook (FB) Files 162.7M Common Shelf for WhatsApp-Related Shareholders
Oct 30, 2014 06:26AM Apple (AAPL) Smartphone Shipments Rose 16.1% in Q3; Xiaomi Breaks into Top Five - IDC (GOOG) (MSFT)
Oct 29, 2014 05:18PM Novavax (NVAX) H7N9 VLP + Matrix-M Granted FDA Fast-Track Designation
Oct 29, 2014 04:21PM FuelCell Energy (FCEL) to Expand Connecticut Facility
Oct 29, 2014 04:20PM Lakeland Industries (LAKE) Updates on Ebola Efforts; Sees 'Significant' Interest in ChemMAX, MicroMAX Lines
Oct 29, 2014 03:33PM Terex (TEX) Announces Joint Venture with Manitex International
Oct 29, 2014 03:01PM Immunomedics (IMMU) Issues Encouraging Update on IMMU-132
Oct 29, 2014 02:57PM American Realty Capital Properties (ARCP) to Hold Conference Call Today
Oct 29, 2014 02:29PM Lannett (LCI) Letrozole Tabs ANDA Approved by FDA
Oct 29, 2014 02:13PM WI-LAN (WILN) Unit to Acquire Semi Packing IP Portfolio from ROHM Co.
Oct 29, 2014 02:08PM Pfizer (PFE): First Vaccine Approved by FDA to Prevent Serogroup B Meningococcal Disease
Oct 29, 2014 01:43PM Apple (AAPL) in preliminary talks with Iran distributors for the iPhone - WSJ
Oct 29, 2014 01:34PM Bank of America's (BAC) Moynihan Said Mortgage Problems 'Behind Them'
Oct 29, 2014 12:34PM Starboard Sends Letter to RealD (RLD); Urges Reconsideration of Acquisition Proposal
Oct 29, 2014 11:59AM ATK (ATK) to Evaluate Plans on Unit Merger with Orbital (ORB) Following Rocket Disaster
Oct 29, 2014 11:55AM Twitter (TWTR), IBM (IBM) Enter Agreement on Data
Oct 29, 2014 11:55AM Twitter (TWTR), IBM (IBM) Enter Agreement on Data
Oct 29, 2014 11:47AM Axion Power (AXPW) Closes 1.88M Common, Warrants Offering
Oct 29, 2014 11:25AM BlackBerry (BBRY) CEO Chen Announces 'BlackBerry Classic'
Oct 29, 2014 11:05AM Hewlett-Packard (HPQ) Unveils 3D Printing System
Oct 29, 2014 11:05AM Hewlett-Packard (HPQ) Unveils 3D Printing System
Oct 29, 2014 09:56AM Ormat Technologies (ORA), Ormat Industries Considering Group Reorganization
Oct 29, 2014 09:52AM Vanda Pharmaceuticals (VNDA) Prices 5M Offering at $11.60/Share
Oct 29, 2014 11:05AM Hewlett-Packard (HPQ) Unveils 3D Printing System
Oct 29, 2014 09:31AM Electronics for Imaging (EFII) Acquires Key IP Assets from Polymeric Imaging
Oct 29, 2014 09:29AM Exact Sciences (EXAS) Reports Cologuard Will be Offered by Meriter-UnityPoint Health
Oct 29, 2014 09:26AM InspireMD (NSPR) MGuard Prime EPS Amended IDE Submission Approved by FDA
Oct 29, 2014 09:23AM Applied Materials (AMAT) Sees Delay in Closing Merger
Oct 29, 2014 09:12AM Metalico (MEA) Says Stock Declines Tied to Aggressive Short Selling
Oct 29, 2014 09:11AM UPDATE: Fiat Chrysler Automobiles (FCAU) Plans to Spin off Ferrari
Oct 29, 2014 09:09AM NQ Mobile (NQ) Enters Reseller Agreement with SoftBank Commerce & Service
Oct 29, 2014 09:11AM UPDATE: Fiat Chrysler Automobiles (FCAU) Plans to Spin off Ferrari
Oct 29, 2014 09:03AM UPS (UPS) Sees Peak Holiday Volume Up 11%
Oct 29, 2014 08:45AM Urstadt Biddle Properties (UBA) Prices 2.5M Common Offering at $21.30/Share
Oct 29, 2014 08:44AM FireEye (FEYE), Verizon (VZ) Enter Mobile Security Arrangement
Oct 29, 2014 08:37AM Kamada's (KMDA) Glassia Receives FDA Orphan Drug Desgination
Oct 29, 2014 08:32AM Pfizer (PFE) Reports Significant Data from PRISTIQ v. Placebo as Sexual Function Treatment in MDD
Oct 29, 2014 08:16AM Versar (VSR) Unit Awarded $3.5M AFRC Contract to Update Existing FOCUS Studies
Oct 29, 2014 08:12AM Arena Pharma (ARNA) Gains; Reports Results of Investigational Pilot Study of Coadministration of Lorcaserin and Phentermine
Oct 29, 2014 08:11AM Miller Energy Resources (MILL) CFO Resigns; Updates on Operations
Oct 29, 2014 07:44AM Orbital Sciences (ORB) Issues Statement on Orb-3 Launch Mishap
Oct 29, 2014 07:22AM Aerohive Networks (HIVE) Clarifies Apple-Related PR
Oct 29, 2014 07:08AM Plug Power (PLUG) Reports Deployment of GenDrive Cells by Golden State Foods
Oct 29, 2014 07:04AM American Realty Capital Properties (ARCP) Announces non-Reliance of Certain Financial Statements
Oct 29, 2014 07:01AM Cara Therapeutics (CARA) Reports Positive Data from HAL Trial of CR845 IV Formulation
Oct 29, 2014 06:47AM SPX Corp (SPW) to Spin-Of Flow Business
View Older Stories